Senators Raise Concerns About Mylan’s EpiPen Price Hike and Expanded Patient Assistance Program
Patient assistance program allows company to increase drug prices while passing costs onto insurance companies and consumers
WASHINGTON, D.C. – In a letter sent today to the CEO of pharmaceutical company Mylan, U.S. Senator Tammy Baldwin, along with 19 other senators, expressed serious concerns about the company’s recent significant price hikes for the life-saving EpiPen Auto-Injector. The senators raised questions about Mylan’s decision to expand its patient assistance program, which allows the company to sharply increase prices while passing the cost of these increases onto insurance companies and ultimately to consumers, and to introduce an authorized generic EpiPen at more than half the price of the branded EpiPen. The letter was signed by Senators Elizabeth Warren (D-MA), Tammy Baldwin (D-WI), Richard Blumenthal (D-CT), Barbara Boxer (D-CA), Sherrod Brown (D-OH), Joe Donnelly (D-IN), Richard J. Durbin (D-IL), Al Franken (D-MN), Heidi Heitkamp (D-ND), Mazie K. Hirono (D-HI), Amy Klobuchar (D-MN), Patrick Leahy (D-VT), Edward Markey (D-MA), Chris Murphy (D-CT), Jack Reed (D-RI), Bernie Sanders (I-VT), Brian Schatz (D-HI), Jon Tester (D-MT), Tom Udall (D-NM), and Sheldon Whitehouse (D-RI).
“The EpiPen…has become so exorbitantly expensive that access to this life saving combination product is in jeopardy for many Americans,” the senators wrote. “Mylan’s near monopoly on the epinephrine auto-injector market has allowed you to increase prices well beyond those that are justified by any increase in the costs of manufacturing the EpiPen.”
“When patients receive short-term co-pay assistance for expensive drugs, they may be insulated from price hikes, but insurance companies, the government, and employers still bear the burden of these excessive prices. In turn, those costs are eventually passed on to consumers in the form of higher premiums, but the drug company is no longer in the spotlight. Because couponing can massively inflate costs, this practice has been outlawed by the government in Medicare and Medicaid. But couponing practices are perfectly legal for commercial insurance and Affordable Care Act exchange coverage.”
The senators requested that Mylan answer a series of questions to provide additional information about the impact that the EpiPen price hike and the associated changes in Mylan’s patient assistance program and other accessibility programs will have on consumers and on taxpayers.
Press Releases by Tammy Baldwin
U.S. Senator Tammy Baldwin Releases Statement on Nomination of Wealthy Insider with Deep Roots on Wall Street for Treasury SecretaryNov 30th, 2016 by Tammy Baldwin
“Wisconsin families struggling to get ahead do not want foxes guarding the hen house.”
Legislation aids Great Lakes communities by delivering next generation coastal data
U.S. Senator Tammy Baldwin Votes for Bipartisan Reform to Increase Access to High Quality Health Care in Rural WisconsinNov 29th, 2016 by Tammy Baldwin
Rural communities in Wisconsin and across the country face many challenges in accessing high-quality health care.
U.S. Senators Tammy Baldwin, Jeanne Shaheen, Ed Markey, and Joe Donnelly Call for Investments to Fight Opioid Epidemic in 21st Century Cures ActNov 23rd, 2016 by Tammy Baldwin
In the letter to Majority Leader McConnell and Minority Leader Reid, the Senators stressed the need to provide immediate funding to address the opioid epidemic.
U.S. Senator Tammy Baldwin and Mayor Tom Barrett Announces $6 Million for Workforce Development to Employ MilwaukeeNov 17th, 2016 by Tammy Baldwin
The funds will be used to train 1,430 individuals, and coordinate regional planning to attract and retain businesses.
U.S. Senator Tammy Baldwin Calls on President-Elect Trump to Keep His Promise to Make Washington Work for Wisconsin, Not Wall StreetNov 17th, 2016 by Tammy Baldwin
Close the revolving door between Wall Street and Washington